Pharmaceutical Companies: R&D Reimagined
Vital Use Case: Accelerating drug discovery through "Gold Standard" longitudinal data. Access real-world evidence (RWE) to study long-term treatment outcomes and patient adherence without the cost of traditional phase IV trials.
Example Cohort
“Type-2 Diabetic patients (Age 45-60) in Urban India with 12+ months of unbroken glucose and activity logs.”
Access Model
Rent-to-Insight
Time-bound licenses (e.g., 6 or 12 months) purchased with $KAV. Tokens are staked in escrow; access automatically expires via Smart Contract once the term ends.
Buyer Deliverables
Research Dashboard
Visualized patient journey trends and anomaly detection.
Secure API
Exportable, anonymized CSV/JSON datasets compatible with R and Python analysis tools.
No raw medical data on-chain
Time-bound access only
Consent-first by design
Enterprise-grade auditability